Glenmark Pharmaceuticals Ltd’s Ichnos Glenmark Innovation submits U.S. FDA IND for solid-tumor candidate ISB 2301
- ISB 2301 is an investigational multispecific immune cell activator targeting three tumor-associated antigens and engaging T cells and natural killer cells.
- IGI plans to start a Phase 1 trial in patients with solid tumors in 2027.
